Back to searchBackground Papers0
Result Papers0
Derived Papers0
Unknown Papers7
The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function
NCT02473809
PHASE4INTERVENTIONAL
University of Aarhus
60 participants
Started 2015-08 · Completed 2017-10
Status: Completed (as of 12-23-2025)
Conditions
Diabetes ComplicationsOsteoporosis
Interventions
Linked Papers (from SciSciNet-V2)
Total Papers7
Background
0Result
0Derived
0Unknown
7Total Citations Per Year
Brief Summary
The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a positive effect on bone, this may be one among other factors to consider before the decision about specific treatment of type 2 diabetes is made for the individual patient.
Sort by:
Background Papers0
No background papers linked
Result Papers0
No result papers linked
Derived Papers0
No derived papers linked
Unknown Papers7
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis
2006
1,662 citations
Type 2 diabetes and bone
2012
322 citations
The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
2007
269 citations
Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials
2014
167 citations
Diabetes, fracture, and bone fragility
2007
95 citations
GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia
2011
84 citations
The Effects of Glucagon-like Peptide-I (GLP-I) on Hormone Secretion from Isolated Human Pancreatic Islets
1995
65 citations